European equities traded in the US as American depositary receipts opened the week slightly lower late Monday morning, declining 0.17% to 1,511.94 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Genfit (GNFT) and pharmaceutical company Novo Nordisk (NVO), which climbed 12% and 5.1%, respectively. They were followed by biotech firm Evaxion (EVAX) and biopharmaceutical company argenx (ARGX), which were up 2.8% and 1.4%, respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company Grifols (GRFS), which lost 3.4% and 1.6%, respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which dropped 1.5% and 1.4%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and NuCana (NCNA), which advanced 22% and 7.4%, respectively. They were followed by biopharmaceutical company Amarin (AMRN) and software firm Endava (DAVA), which rose 3.4% and 2.5%, respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and pharmaceutical company Silence Therapeutics (SLN), which fell 6.5% and 1.6%, respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and mining company BHP Group (BHP), which were down 1% each.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。